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Abstract. Malignant melanoma is a lethal form of skin 
cancer and highly metastatic tumor with poor prognosis; 
BEL β-trefoil, a lectin, obtained by our group, possesses 
the ability to act specifically on malignant cells. Therefore, 
the aim of our study was to investigate the effects of BEL 
β-trefoil in melanoma cells in an attempt to evaluate its poten-
tial usage as anticancer agent. BEL β-trefoil was purified by 
chromatography and A375 and MeWo melanoma cells were 
treated. Viability and proliferation were evaluated as well as 
apoptosis, RUNX2 gene expression and migration ability. The 
treated tumor cells decreased viability as well as proliferative 
ability. Flow cytometry analysis showed a lessen effect of the 
treatment on apoptosis. The gene expression analysis showed 
a reduction of RUNX2 expression in a dose-dependent 
manner and migration ability was reduced significantly in 
both treated cell lines. Our findings suggest that BEL β-trefoil 
can be considered a useful tool against malignancy due to 
its effect based on the simultaneous proliferation ability 
reduction as well as the inhibition of migration capacity on 
melanoma tumor cells.
Introduction
Lectins can act specifically on malignant cells thanks to 
the presence on the surface of transformed cells of the 
Thomsen-Friedenreich antigen or T-antigen, a disaccharide, 
Galβ1-3GalNAc. This disaccharide, that is hidden in normal 
cells (1), allows selective binding of lectins through serine or 
threonine of glycoproteins.
Mushroom derived lectins have been considered to this 
purpose by taking advantage of their ligand-binding speci-
ficity (2). For instance, Agaricus bisporus, a lectin contained 
in edible mushrooms, has been shown to selectively inhibit the 
proliferation of human malignant epithelial cell lines without 
toxicity for normal cells (3).
Recently, we obtained a lectin with antineoplastic proper-
ties from the wild mushroom Boletus edulis (4). This protein 
was named Boletus edulis lectin (BEL) β-trefoil and it could 
represent an interesting tool for therapeutic applications 
against cancer.
Malignant melanoma is a lethal type of cancer with an 
incidence that is increased in the last decades (1). It is a highly 
metastatic tumor generally resistant to apoptosis as well as 
to chemotherapeutic treatments and local tumor surgery. 
Radiotherapy and chemotherapy are the standard treatment 
used. Since metastatic melanoma has a poor prognosis, the 
challenge is to develop new and more effective therapeutic 
tools.
Transcription factors have been considered in recent years 
crucial targets in strategies against this malignancy, as well as 
other cancer types.
Among other transcription factors, RUNX2 regulates the 
expression of genes involved in tumor progression, invasion 
and metastasis such as osteopontin, bone sialoprotein, and 
collagenases (5). RUNX2 play an important role in tumor 
progression by regulating proliferation, migration and inva-
sion pathways. In melanoma, RUNX2 has been considered 
a molecular regulator of epithelial-to-mesenchymal transi-
tion (6). In general, we found in patients with bone metastases 
an increased expression of RUNX2 gene, suggesting that this 
transcription factor may be considered a mesenchymal stem 
marker for cancer (7).
The aim of this study was to use BEL β-trefoil against 
A375 and MeWo melanoma cells, focusing the study on effects 
in key mechanisms involved in neoplasia, such as apoptosis 
and Ki67 expression as well as migration properties.
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Materials and methods
BEL β-trefoil purification. Commercial king bolete mush-
rooms (Boletus edulis) were homogenized in a blender with 
an equal volume of PBS (10 mM Nah2PO4 ph 7.5 and 
150 mM NaCl) and centrifuged at 7,500 x g for 30 min 
at 4˚c. Proteins in the supernatant were precipitated by 
adding 50% w/v ammonium sulphate, separated from the 
supernatant after centrifugation at 12,000 x g for 15 min at 
4˚c, resuspended and dialyzed in buffer A (20 mM Tris-hcl 
ph 7.5). The protein solution was loaded onto a dEAE-
cellulose column previously equilibrated with buffer A 
and then washed with buffer A containing 30 mM NaCl 
to eliminate contaminants. The fraction containing BEL 
β-trefoil was eluted with 20 mM Tris-hcl ph 7.5, 250 mM 
Nacl and further purified by size exclusion chromatography 
using a Superdex G75 column in 20 mM Tris-hcl ph 7.5, 
150 mM Nacl.
The protein solution, previously equilibrated in buffer A 
was loaded onto a stronger anionic exchanger MonoQ to 
discriminate among isoforms. A linear sodium chloride 
gradient was performed and the most abundant isoform eluted 
with Nacl 90 mM was defined as BEL-β trefoil.
Recombinant BEL β-trefoil expression and purification. 
BEL β-trefoil coding sequence (4) was inserted into pET22b 
plasmid using NdeI and XhoI restriction sites. The construct 
was used to transform E. coli BL21 C41 expression strain 
following a standard heat shock protocol. When cell culture 
reach an Od600 of 0.8 in LB media protein expression was 
induced by adding 0.25 mM IPTG and shacking overnight 
at 20˚c. cells were harvested by centrifugation at 7500 x g, 
lysed by sonication and the soluble fraction was loaded 
onto a Nickel-Sepharose column previously equilibrated 
with buffer B (20 mM Tris-hcl ph 7.5, 500 mM Nacl and 
10 mM imidazole). After washing the column with buffer 
B BEL β-trefoil was eluted with a linear imidazole gradient 
from 10 to 350 mM. Next, thrombin was added to cleave the 
histidine tag. Tag-free protein was separated from the uncut 
through Nickel-Sepharose column.
BEL β-trefoil was then collected, loaded onto Superdex G75 
column and eluted with 20 mM Tris-hcl ph 7.5, 150 mM 
Nacl. The fluorescent BEL β-trefoil was obtained by cloning 
the protein coding sequence into pWaldo-GFP plasmid using 
NdeI and KpnI restriction enzymes; this protocol allowed 
the expression of recombinant BEL β-trefoil fused with a 
c-terminal GFP. After the heat shock transformation of E. coli 
BL21 (dE3) the chimeric protein was expressed and purified 
following the same protocol of BEL β-trefoil alone.
Cells and BEL β-trefoil treatment. A375 and MeWo melanoma 
cells were cultured under humidified atmosphere of 5% cO2 
and passaged in growth medium: dMEM/F12 containing 
10% FBS (fetal bovine serum) supplemented with antibiotics 
(1% penicillin and streptomicyn) and 1% glutamin. cells 
were then harvested using trypsin, washed and counted on a 
microscope using a Burker hemocytometer and plated again 
in growth medium. Once 80% confluence was reached BEL 
β-trefoil at concentration ranging from 0 to 100 µg/ml was 
added.
Cell viability. Cell viability was evaluated by a colorimetric 
assay based on the reduction of the tetrazolium salt XTT 
(sodium 3I-[1-phenylamino-carbonyl-3,4-tetrazolium]-
bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate) by 
mitochondrial dehydrogenase of viable cells to a formazan dye 
(cell proliferation kit II - XTT Roche).
Briefly 100 µl XTT labelling mixture was added to each 
well and cells were incubated at 37˚c in a humidified atmo-
sphere of 5% CO2 for 4 h. The spectrophotometric absorbance 
of the samples was measured every hour using a microtitre 
plate (ELISA) reader at a wavelength of 450 nm.
Real-time PCR. PCR was performed in a total volume of 20 µl 
containing 1X Premix Ex Taq™ (2X), 1X Rox Reference 
dye (50X) and 20 ng of cdNA; probe sets for gene Runx2, 
(hs00231692_m1) actin and GAPdh obtained from Assay-
on-demand Gene Expression Products (Applied Biosystems). 
Real-time RT-PCR reactions were carried out in two-tube 
system and in multiplex.
The amplification conditions included 30 sec at 95˚c 
(initial denaturation), followed by 50 cycles at 95˚c for 5 sec 
(denaturation) and at 60˚c for 31 sec (annealing/extension). 
Thermocycling and signal detection were performed with 
ABI PRISM 7000 Sequence detector (Applied Biosystems). 
Signals were detected according to the manufacturer's instruc-
tions.
As previously reported, the Ct value correlates to the 
starting quantity of target mRNA (8); we selected the ∆Rn in 
the exponential phase of amplification plots to determine the 
ct values. ∆∆Ct values were then calculated with respect to 
control.
To normalize mRNA expression for sample-to-sample in 
RNA input, quality and reverse transcriptase efficiency, we 
amplified the β-actin and β-2 microglobulin housekeeping 
genes. β-actin and β-2 microglobulin endogenous/internal 
control genes were abundant and remained constant propor-
tionally to total RNA among the samples.
Ct data. Ct values for each reaction were determined using 
TaqMan SdS analysis software. For each amount of RNA 
tested, triplicate ct values were averaged. Because ct values 
vary linearly with the logarithm of the amount of RNA, this 
average represents a geometric mean.
Cell proliferation test. Proliferating cell nuclei were identified 
by Ki67-positive immunofluorescence on cells cultured in slide 
glass chambers, acetone fixed and stored at -20˚c. Briefly, cells 
were grown in slides with different BEL β-trefoil concentra-
tions for 48 h under humidified atmosphere of 5% cO2 at 37˚c; 
then, cultured cells were fixed with cold acetone and stored at 
-20˚c. For immunofluorescence, cells were firstly rinsed twice 
in PBS and permeabilized with washing solution (Triton X-100 
0.1% in PBS). After incubating the cells with anti-Ki67 
primary antibody (clone Ki67, dako), the secondary antibody 
(FITc-conjugated rabbit anti-mouse IgG, dako) was applied. 
Finally, the nuclei were counterstained with dAPI (Sigma) 
and observed at 40X objective using Nikon epifluorescence 
microscope. Semiquantitative analysis of protein expression 
was achieved by counting fluorescent cells in three fields of 
each of six slides at magnification of x40. The estimate was 
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calculated as the percentage of positive cells with respect to 
the total dAPI-stained nuclei.
Annexin staining. The exposure of phospholipid phosphatidyl-
serine on the plasma membrane of apoptotic cells was detected 
using the Annexin V-fluorescein isothiocyanate (FITc)/prop-
idium iodide (PI) detection kit (Bender Med System, Vienna, 
Austria), as previously reported (7). Briefly, cells were treated 
with lectin for 48 h. After incubation, cells were trypsinized 
and 250x103 cells were centrifuged and re-suspended in 
500 µl of 1X binding buffer. Next, cells were stained with 
Annexin V-FITc for 10 min. Propidium iodide (PI) was added 
just before the analysis with the FAcScanto™ flow cytometer 
(Bd Biosciences, San Jose, cA, USA). At least 10,000 events 
were acquired and samples were analyzed by FlowJo software 
(TreeStar, Ashland, OR, USA). Viable cells were defined as 
Annexin V-negative and PI-negative; early apoptotic cells 
were defined as Annexin V-positive and PI-negative; late 
apoptotic/necrotic cells were defined as Annexin V-positive 
and PI-positive.
Migration assay. Transwell plates with 8-µm pore size 
membranes (corning, NY, USA) were used to analyze cell 
migration, according to the mmanufacturer's instructions. 
A375 and MeWo cells in RPMI with or without BEL β-trefoil 
were added to the top of the Transwell inserts and cultured 
for 48 h in humidified environment with 5% cO2 at 37˚c. 
Migrated cells (passed through polyethylene membrane) were 
fixed with methanol and stained with a 0.1% crystal violet 
solution and counted in six random fields.
Statistical analysis. Results are expressed as mean ± SE. The 
Wilcoxon test was used for non-parametric data. For analysis 
of treatment responses, multiple measurement ANOVA 
followed by Bonferroni as post hoc analysis was performed. 
A probability value of <0.05 was considered statistically 
significant. Spearman correlation coefficient and regression 
curve estimations were performed when indicated. Analyses 
were applied to experiments carried out at least three times. 
Statistical analyses were performed using SPSS for Windows, 
version 16.0 (SPSS Inc, chicago, IL, USA).
Results
Cells viability, apoptosis and proliferation. Recombinant-
fluorescent BEL β-trefoil entered the cells after 24 h at 
concentration starting from 20 to 80 µg/ml (Fig. 1a). In order 
to study the effect of the treatment, we analyzed cell viability 
by XTT test in cells incubated at 37˚c and exposed to BEL 
β-trefoil up to 80 µg/ml. After 48 h we observed a dose-depen-
dent reduction of cell viability. The BEL β-trefoil decreased 
cell viability in a manner of statistical significance versus non-
treated cells when it was added at 20 µg/ml (p<0.05), 40 and 
80 µg/ml (p<0.01) (Fig. 1b).
To clarify whether BEL β-trefoil effect was pro-apoptotic 
or/and it inhibited proliferation, we evaluated the exposure 
of the phospholipid phosphatidylserine on the plasmatic 
membrane (apoptotic feature) by annexin staining and the 
proliferation index by in situ expression of Ki67 protein 
(proliferative marker).
We observed an apoptotic induction in treated compared 
to untreated cells. In fact Annexin V staining confirmed cell 
reduction showed by XTT assay in both cell lines even if the 
difference was not statistically significant (Fig. 2).
When proliferating cells were evaluated by Ki67 immu-
nofluorescence, positively stained nuclei were reduced in 
treated A375 and MeWo cells as compared to non-treated 
cells. This proliferative reduction was statistical significant 
in both cell lines treated with 20 and 40 µg/ml of BEL 
β-trefoil (Fig. 3)
Migration ability and RuNX2 gene expression. RUNX2 
expression has been shown to be involved in promoting migra-
tion of melanoma cells. To evaluate if BEL β-trefoil treatment 
would modulate RUNX2 expression, we treated both MeWo 
and A375 lines with increasing doses up to 80 µg/ml. After 
24 h of treatment Runx2 gene expression was significantly 
reduced in treated cells already from 40 µg/ml of BEL β-trefoil 
(p<0.05) (Fig. 4).
To evaluate the impact of exposing cells to BEL β-trefoil 
on migration ability, we cultured the cells in Transwell plates. 
As shown in Fig. 5, the presence of lectin significantly reduced 
cell migration in both cell lines either at 40 (p<0.05) or at 80 
(p<0.01) compared to untreated cells after 24 h of treatment.
Figure 1. BEL β-trefoil effect on melanoma cell viability. (a) After 24 h of 
treatment at 20 µg/ml, recombinant-fluorescent BEL β-trefoil was endocy-
tosed by almost all cells. Nuclei were counterstained with dAPI. (b) Viability 
was analyzed by XTT test in both cell lines at increasing concentrations of 
BEL β-trefoil as indicated. After 48 h a dose-dependent reduction of cell 
viability was observed. *p<0.05, #p<0.01.
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Figure 2. BEL β-trefoil effect on melanoma cell apoptosis. (a) Apoptosis was analyzed by Annexin V/PI flow cytometry assay. cell lines A375 and MeWo were 
stimulated with 20, 40 or 80 µg/ml of lectin, stained with Annexin V/PI and then analyzed by flow cytometry. comparison between treatments was performed 
using the Kruskal-Wallis test with dunn's post hoc test. NS, not significant. (b) Representative example of Annexin V/PI flow cytometry analysis.
Figure 3. BEL β-trefoil effect on the proliferative rate of melanoma cells. (a) Proliferating cells were evaluated by Ki67 immunofluorescence stained nuclei in 
both cell lines treated with 40 µg/ml of BEL β-trefoil. The Ki67 expression was lower in treated A375 (c) and MeWo (d) cells than in untreated cells (A and B). 
(b) The graph shows the proliferative reduction in both cell lines treated with 40 µg/ml of BEL β-trefoil. The reduction of Ki67-positive nuclei was statistically 
significant (p<0.05) in both cell lines.
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Discussion
BEL β-trefoil in vitro treatment affected viability of both 
melanoma cell lines: A375 and MeWo. In order to clarify the 
underlying mechanism, we assayed the treated and untreated 
cells for Ki67 expression as well as for Annexin V-FITc and 
PI staining.
The Ki67 protein is a marker of proliferative activity and 
its overexpression has been correlated with a poor prognosis 
in various tumors, including cutaneous melanoma where Ki67 
immunohistochemical staining is considered a specific and 
sensitive method to diagnose and to predict prognosis (9). 
Our results showed Ki67 expression significantly decreased 
in both treated cell lines, respect to the untreated controls. On 
the contrary, Annexin V-FITc and PI staining performed to 
assess cell apoptosis showed reduced ability of BEL β-trefoil 
in inducing cellular death, in both melanoma cells. Taken 
together, these results demonstrated that BEL β-trefoil treat-
ment reduces cell viability mainly by affecting proliferative 
activity rather than by inducing apoptosis. On the other hand, 
a pro-apoptotic effect should not be completely ruled out 
since melanomas are thought to redundantly prevent apoptosis 
by upregulating multiple signaling pathways. constitutive 
signaling mediated by Ras, MAPKs (10,11) and involving 
PI3K could be acting on Fas cascade (12) minimizing pro-
apoptotic signaling mediated by the lectin. Yet, the inhibitory 
effect on cell proliferation was more striking in both, A375 
and MeWo cells.
Recently, the involvement of the transcription factor 
RUNX2 in melanomagenesis was demonstrated at multiple 
levels, including cell proliferation (13). RUNX2 was overex-
pressed by melanoma cell lines and its down modulation by 
siRNA, inhibited migration ability.
Interestingly, the treatment with lectin decreased RUNX2 
expression in both cell lines and the effect was dose-dependent. 
The role of RUNX2 in the different steps of malignancies has 
been largely demonstrated for inducing gene expression of 
molecular targets associated to tumor progression, invasion, 
metastasis as well as migration and invasion. Additionally, 
RUNX2 regulates transcription factors such as SOX9, SNAI2 
and SMAd3 involved in epithelial to mesenchymal transi-
tion (EMT) process (14).
In accordance with the role of RUNX2 on cell migration 
demonstrated in other systems, we observed that treating 
melanoma cells with BEL β-trefoil simultaneously and dose-
dependently affected RUNX2 expression and migration ability 
in both melanoma cell lines.
Even if in recent years melanoma treatment has improved 
by the development of immunological approaches, a certain 
percentage of melanoma affected patients are unresponsive to 
imunotherapy (15).
In conclusion, this study showed that BEL β-trefoil 
inhibited cell viability through cytostatic effects and reduced 
migration ability in melanoma cells.
Further studies are required to elucidate BEL β-trefoil 
molecular mechanism, nonetheless it could represent a valid 
alternative therapeutic approach to treat melanoma based on 
its inhibitory effects on proliferation and migration.
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